From the recently acquired St. Jude stable, now in Abbott’s hands, Assurity now lays claim to being the World’s smallest, longest-lasting wireless MRI-compatible pacemaker
BurstDR stimulation targets chronic pain patients with a new therapy option designed to provide less pain, less suffering and less therapy maintenance
The AMPLATZER™ Amulet™ IDE trial aims to deliver data that will support FDA approval of the device, increasing treatment options for U.S. AF patients at risk of stroke
SyncAV™ CRT technology provides further advantages to support physicians seeking new treatment options for heart failure patients
St. Jude Medical, Inc., has achieved U.S. FDA approval and announced the launch of its SyncAV™ CRT software which it says will enhance its already comprehensive cardiac resynchronization therapy portfolio.
Cardio device titan will now proceed to EU launch of range adds, claiming largest portfolio of quadripolar leads
“…access to a highly advanced pacemaker that can undergo an MRI scan is a notable step forward in treatment options”
Quadra Assura MP™ CRT-D, Quadra Allure MP™ CRT-P and additional Quartet™ LV lead options broaden the St. Jude Medical industry-leading heart failure portfolio in the U.S.
Proclaim™ Elite is first and only upgradeable and non-rechargeable SCS system approved to deliver burst stimulation
Patient-centric, recharge-free, upgradeable, MR-conditional, the Proclaim™ Elite SCS System targets patients’ quality of life
The latest approval increases patient access to St. Jude’s TAVR implant that provides excellent patient outcomes and the opportunity to optimize device placement
There’s a high degree of continuity built into St. Jude’s succession plan, Michael Rousseau having been around since 1999 and COO since last year
Data presented at the ESC Congress 2015 supports St. Jude Medical PressureWire Fractional Flow Reserve technology
St. Jude has gained CE mark approval for its Prodigy MRI™ spinal cord stimulation therapy, the first of its kind to offer MRI compatibility and Burst stimulation
In what St. Jude hopes will be a happy marriage, it will acquire the heart assist device company in an all cash transaction that represents a significant premium
CardioMEMS allows patient heart data to be transmitted to health providers who can then manage medication to reduce hospitalization risk